The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2019 | Longer-term follow-up in CAR-T trials
David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses that we are now getting a longer-term follow-up in key CAR-T trials for Lymphoma. Namely, the JULIET (NCT02445248) and ZUMA-1 (NCT02348216) trial. Prof. Maloney mentions ongoing trials working to treat patients at an earlier disease state and in other histologies. Lisocabtagene maraleucel is being targeted in chronic lymphocytic leukemia (CLL). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2018, held in Amsterdam, Netherlands.
